Kantar, the world’s leading data, insights and consulting group, today entered into an agreement for the sale of its global Health division to Cerner in an all-cash transaction for $375 million.
Cerner is a global healthcare technology company with a focus on using data for wide-reaching applications in life sciences, pharmaceuticals and healthcare at large.
Commenting on the announcement Ian Griffiths, Deputy CEO and CFO, commented: “The people, products and services of Kantar’s Health division are admired across the industry. With its leadership in ‘real world evidence’ and therapeutic expertise, especially in oncology and rare diseases, the growth opportunities of the division will be best realised as part of a healthcare specialist. As part of Cerner, the Health division will enable a step-change in Cerner’s data analytics strategy and capabilities, providing an increased impact on health outcomes for patients around the world. In addition to the advantages for Kantar Health, the transaction enables the Kantar Group to increase focus on its identified growth priorities.”
The proposed transaction is anticipated to complete during the first half of 2021 subject to completion of the relevant shareholder, legal and regulatory processes, and subject to the outcome of employee information and employee representatives’ consultation processes where necessary.
